Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila M Fleming

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Current Environmental Health Reports|April 19, 2017
Mechanisms of Gene-Environment Interactions in Parkinson's DiseaseSheila M Fleming
Journal of Parkinson'S Disease|August 13, 2013
Cardiovascular autonomic dysfunction in animal models of Parkinson's diseaseSheila M Fleming
International Review of Neurobiology|November 11, 2009
Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disordersSheila M Fleming
Handbook of Clinical Neurology|February 21, 2023
Role of rodent models in advancing precision medicine for Parkinson's diseaseEmily Simons, Sheila M Fleming
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2014
Cinnamon in a mouse model of PD: Khasnavis S, Pahan K. Cinnamon protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol 2014;9:569-581Sheila M Fleming, Alberto J Espay
Movement Disorders : Official Journal of the Movement Disorder Society|May 29, 2014
Ribosomal s15: A novel therapeutic target for Parkinson's diseaseSheila M Fleming, Alberto J Espay
Frontiers in Neurology|January 22, 2024
ATP13A2 (PARK9) and basal ganglia functionKristina M Croucher, Sheila M Fleming
Behavioural Pharmacology|August 31, 2006
Behavioral phenotypes and pharmacology in genetic mouse models of ParkinsonismSheila M Fleming, Marie-Françoise Chesselet
Behavioural Brain Research|December 8, 2004
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidateSheila M Fleming, Yvon Delville, Timothy Schallert
Neuropharmacology|November 7, 2021
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapiesSheila M Fleming, Ashley Davis, Emily Simons
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Environmental Health Reports|April 19, 2017
Mechanisms of Gene-Environment Interactions in Parkinson's DiseaseSheila M Fleming
Journal of Parkinson'S Disease|August 13, 2013
Cardiovascular autonomic dysfunction in animal models of Parkinson's diseaseSheila M Fleming
International Review of Neurobiology|November 11, 2009
Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disordersSheila M Fleming
Handbook of Clinical Neurology|February 21, 2023
Role of rodent models in advancing precision medicine for Parkinson's diseaseEmily Simons, Sheila M Fleming
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2014
Cinnamon in a mouse model of PD: Khasnavis S, Pahan K. Cinnamon protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol 2014;9:569-581Sheila M Fleming, Alberto J Espay
Movement Disorders : Official Journal of the Movement Disorder Society|May 29, 2014
Ribosomal s15: A novel therapeutic target for Parkinson's diseaseSheila M Fleming, Alberto J Espay
Frontiers in Neurology|January 22, 2024
ATP13A2 (PARK9) and basal ganglia functionKristina M Croucher, Sheila M Fleming
Behavioural Pharmacology|August 31, 2006
Behavioral phenotypes and pharmacology in genetic mouse models of ParkinsonismSheila M Fleming, Marie-Françoise Chesselet
Behavioural Brain Research|December 8, 2004
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidateSheila M Fleming, Yvon Delville, Timothy Schallert
Neuropharmacology|November 7, 2021
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapiesSheila M Fleming, Ashley Davis, Emily Simons
Pageof 6